Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Algorae Pharmaceuticals to Partner with Dr Reddy’s for Australian Supply of Chemotherapy Medicine
Algorae Pharmaceuticals (ASX: 1AI) has signed a distribution partnership with Indian multinational Dr Reddy’s Laboratories to supply chemotherapy medicine capecitabine to the Australian market.
Latest Stories
Proteomics International Confirms US Reimbursement Price for ProMarkerD Diabetic Kidney Disease Test
Proteomics International Laboratories (ASX: PIQ) has announced that the US Centres for Medicare & Medicaid Services has set a US$390.75 reimbursement price for its PromarkerD predictive test for diabetic kidney disease.
Aroa Biosurgery Reports NZ$44.9m in Product Revenue for First Six Months of FY26
Aroa Biosurgery (ASX: ARX) has reported total product revenue of NZ$44.9 million for the first six months of financial year 2026, representing growth of 14% on the previous corresponding period.
Argenica Therapeutics Validates Efficacious ARG-007 Dose in New Pre-Clinical Stroke Study
Argenica Therapeutics (ASX: AGN) has released new data from an independent pre-clinical study validating the efficacy and dosing of lead neuroprotective peptide candidate ARG-007 for ischaemic stroke.
Island Pharmaceuticals Joins Medical Countermeasures Coalition to Advance Galidesivir Against High-Priority Virus Threats
Island Pharmaceuticals (ASX: ILA) has been granted membership into the US-based Medical Countermeasures Coalition, an important milestone in its strategy to advance lead candidate galidesivir as a critical countermeasure against high-priority virus threats.
Lumos Diagnostics Secures Full US Medicare Reimbursement Recognition for FebriDx Test
Lumos Diagnostics (ASX: LDX) has achieved complete US Medicare reimbursement recognition for its FebriDx point-of-care diagnostic test, securing coverage from all seven Medicare Administrative Contractors.
Orthocell Reports Accelerated Adoption of Remplir Nerve Repair Technology by Australian Surgeons
Orthocell (ASX: OCC) has confirmed accelerating adoption of lead product Remplir by Australian urologists, with the product so far used in approximately 100 prostate cancer surgeries nationwide to assist in post-surgical complications from peripheral nerve injury.
EVE Health Signs Telehealth Agreement with hubMed to Support Dyspro and Libbo Launches
EVE Health Group (ASX: EVE) has entered into a telehealth services agreement with hubMed to enhance the quality and continuity of care for patients using EVE’s therapeutic products including Dyspro for dysmenorrhoea and Libbo for erectile dysfunction.
BCAL Diagnostics on Track for Australian Launch of Aventect Pancreatic and Ovarian Cancer Tests
BCAL Diagnostics (ASX: BDX) is on track to launch the cutting-edge Avantect pancreatic and ovarian cancer tests onto the Australian market in the new year.
Radiopharm Theranostics Granted Ethics Approval for RAD402 Phase 1 Trial to Treat Advanced Prostate Cancer
Radiopharm Theranostics (ASX: RAD) has received Bellberry human research ethics committee approval in Australia for a Phase 1 first in-human clinical trial of RAD402 for the treatment of metastatic or locally-advanced prostate cancer.
Island Pharmaceuticals Employs FDA Animal Rule in Development of Galidesivir to Counter Deadly Marburg Virus
Island Pharmaceuticals (ASX: ILA) has been granted an opportunity to advance approval of its lead candidate Galidesivir under the US Food and Drug Administration’s Animal Rule.
Biotron Advances Hepatitis B Program with Strong Clinical Results Across Key HBV Markers
Biotron (ASX: BIT) has reported a major step forward in its Hepatitis B Virus drug development program, confirming robust antiviral activity for its lead compound BIT-HBV001 across two established mouse models and multiple in vitro assays.